Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Genmab A/S

The latest update is out from Genmab ( ($GMAB) ). Genmab A/S, the Copenhagen-headquartered biotech specializing in antibody-based cancer therapies ...

Genmab Discloses Orbis as 4.99% Major Shareholder

UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,600.00. According to TipRanks, Deng is a 5-star an...

UBS Remains a Buy on Genmab A/S (0MGB)

Genmab ( ($GMAB) ) just unveiled an update. Following its Annual General Meeting on March 19, 2026, Genmab’s board reconstituted itself, appointing...

Genmab Reshapes Board Leadership and Approves New Employee Equity Grants After 2026 AGM

Genmab ( ($GMAB) ) has issued an announcement. Genmab A/S, the Danish antibody-focused biotechnology group, held its Annual General Meeting (AGM) o...

Genmab Shareholders Approve 2025 Results and Capital Reduction at March 19 AGM

The latest update is out from Genmab ( ($GMAB) ). Genmab A/S has completed a previously announced share buy-back program initiated on February 17, ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMAB	$28.35	+2.51%	1.55M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMAB	$28.35	+2.5%	1.55M
3
4
5
6

GMAB

GMAB

No Data Available

Get Genmab A/S Data in Excel

Get Genmab A/S Data in Excel